Chapter 6 Molecular and Cell Biology of Testicular Germ Cell Tumors

International Review of Cell and Molecular Biology

Volumn 278, Issue C, 2009, Pages 277-308

  Chieffi, Paolo ^a   Franco, Renato ^b   Portella, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gonocytes; Kinase inhibitors; Testicular cancer; Testicular germ cells; Testis

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; ALPHA FETOPROTEIN; AURORA KINASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOKERATIN; HESPERADIN; HESPERADIN 8; HIGH MOBILITY GROUP A2 PROTEIN; IMATINIB; LACTATE DEHYDROGENASE; MUCOPROTEIN; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PESTICIDE; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX; TUMOR MARKER; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VINBLASTINE; ZINC FINGER PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER REGRESSION; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLOGY; DIAGNOSTIC ACCURACY; EMBRYONAL CARCINOMA; ENVIRONMENTAL FACTOR; GERM CELL TUMOR; HEREDITY; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NEUTROPENIA; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SEMINOMA; TESTIS NONSEMINOMA CANCER; TESTIS TERATOMA; TROPHOBLASTIC TUMOR; TUMOR CLASSIFICATION; YOLK SAC TUMOR; GENETICS; MALE; NEOPLASM; PATHOLOGY; TESTIS TUMOR;

CELL BIOLOGY; HUMANS; MALE; MOLECULAR BIOLOGY; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 73349136302     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1937-6448(09)78006-2     Document Type: Review

References (134)

1. Al Ghamdi A.M., and Jewett M.A. Stage I nonseminomatous germ cell tumours: the case for management by risk stratification. Can. J. Urol. 12 (2005) 62-65
2. Almstrup K., Hoei-Hansen C.E., Wirkner U., Blake J., Schwager C., Ansorge W., et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 64 (2004) 4736-4743
3. Atlasi Y., Mowla S.J., Ziaee S.A., Gokhale P.J., and Andrews P.W. OCT4 spliced variants are differentially expressed in human pluripotent and non-pluripotent cells. Stem Cells 26 (2008) 3068-3074
4. Avilion A.A., Nicolis S.K., Pevny L.H., Perez L., Vivian N., and Lovell Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 17 (2003) 126-140
5. Bahrami A., Ro J.Y., and Ayala A.G. An overview of testicular germ cell tumors. Arch. Pathol. Lab. Med. 131 (2006) 1267-1280
6. Balzer B.L., and Ulbright T.M. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am. J. Surg. Pathol. 30 (2006) 858-865
7. Barbagallo F., Baronetto M.P., Franco R., Chieffi P., Dolci S., Fry A.M., et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J. Pathol. 217 (2009) 431-441
8. Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., et al. Dicer is essential for mouse development. Nat. Genet. 35 (2003) 215-217
9. Berthelsen J.G., Skakkebaek N.E., von der Maase H., Sorensen B.L., and Mogensen P. Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer. Br. Med. J. 285 (1982) 1683-1686
10. Beyer J., Kramar A., Mandanas R., Linkesch W., Greinix A., Droz J.P., et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol. 14 (1996) 2638-2645
11. Boiani M., and Scholer H.R. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 6 (2005) 872-884
12. Bonner M.R., McCann S.E., and Moysich K.B. Dietary factors and the risk of testicular cancer. Nutr. Cancer 44 (2002) 35-43
13. Burke A.P., and Mostofi F.K. Spermatocytic seminoma: a clinicopathologic study of 79 cases. J. Urol. Pathol. 1 (1993) 21-32
14. Carmena M., and Earnshaw W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 4 (2003) 842-854
15. Carmena M., and Earnshaw W.C. INCENP at the kinase crossroads. Nat. Rev. Cell Biol. 8 (2006) 110-111
16. Chaganti R.S., and Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 60 (2000) 1474-1482
17. Chieffi P. Molecular targets for the treatment of testicular germ cell tumors. Mini Rev. Med. Chem. 7 (2007) 755-759
18. Chieffi P., Troncone G., Caleo A., Libertini S., Linardopoulos S., Tramontano D., et al. Aurora B expression in normal testis and seminomas. J. Endocrinol. 181 (2004) 263-270
19. Chung P., Parker C., Panzarella T., Gospodarowicz M.K., Jewett S., Milosevic M.F., et al. Surveillance in stage I testicular seminoma. Can. J. Urol. 9 (2002) 1637-1640
20. Classen J., Souchon R., Hehr T., and Bamberg M. Treatment of early stage testicular seminoma. J. Cancer Res. Clin. Oncol. 127 (2001) 475-481
21. Comiter C.V., Kibel A.S., Richie J.P., Nucci M.R., and Renshaw A.A. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J. Urol. 159 (1998) 59-863
22. de Jong J., and Looijenga L.H. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit. Rev. Oncog. 12 (2006) 171-203
23. de Jong J., Stoop H., Dohle G.R., Bangma C.H., Kliffen M., van Esser J.W., et al. 4/4 for pre-invasive and invasive testicular germ cell tumours. J. Pathol. 206 (2005) 242-249
24. de Jong J., Stoop H., Gillis A.J., van Gurp R.J., van de Geijn G.J., Boer M., et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J. Pathol. 215 (2008) 21-30
25. Dieckmann K.P., and Pichlmeier U. Is risk of testicular cancer related to body size?. Eur. Urol. 42 (2002) 564-569
26. Dieckmann K.P., Endsin G., and Pichlmeier U. How valid is the prenatal estrogen excess hypothesis of testicular germ cell cancer? A case control study on hormone-related factors. Eur. Urol. 40 (2001) 677-683
27. Dieckmann K.P., Hartmann J.T., Classen J., Lüdde R., Diederichs M., and Pichlmeier U. Tallness is associated with risk of testicular cancer: evidence for the nutrition hypothesis. Br. J. Cancer 99 (2008) 1517-1521
28. Dieckmann K.P., Hartmann J.T., Classen J., Diederichs M., and Pichlmeier U. Is increased body mass index associated with the incidence of testicular germ cell cancer?. J. Cancer Res. Clin. Oncol. 135 (2009) 731-738
29. Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. System and male genital organs (2004), IARC Press, Lyon, France pp. 218-249
30. Einhorn L.H., and Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87 (1977) 293-298
31. Ekbom A., Richiardi L., Akre O., Montgomery S.M., and Sparén P. Age at immigration and duration of stay in relation to risk for testicular cancer among Finnish immigrants in Sweden. J. Natl. Cancer Inst. 95 (2003) 1238-1240
32. Emerson R.E., and Ulbright T.M. Morphological approach to tumours of the testis and paratestis. J. Clin. Pathol. 60 (2007) 866-880
33. Esposito F., Libertini S., Franco R., Abagnale A., Marra L., Portella G., et al. Aurora B expression in post-puberal testicular germ cell tumours. J. Cell. Physiol. 221 (2009) 435-439
34. Fedele M., Franco R., Salvatore G., Baronetto M.P., Barbagallo F., Pero R., et al. PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J. Pathol. 215 (2008) 39-47
35. Feldman D.R., Bosl G.J., Sheinfeld J., and Motzer R.J. Medical treatment of advanced testicular cancer. JAMA 299 (2008) 672-684
36. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
37. Ferreiro J.A. Ber-H2 expression in testicular germ cell tumors. Hum. Pathol. 25 (1994) 522-524
38. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer 32 (1996) 2534-2539
39. Forman D., Oliver R.T., Brett A.R., Marsh S.G., Moses J.H., Bodmer J.G., et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer 65 (1992) 255-262
40. Franco R., Esposito F., Fedele M., Liguori G., Pierantoni G., Botti G., et al. Detection of high mobility group proteins A1 and A2 represents a valid diagnostic marker in post-puberal testicular germ cell tumours. J. Pathol. 214 (2008) 58-64
41. García-Rodríguez J., García-Martín M., Nogueras-Ocaña M., de Dios Luna-del-Castillo J., Espigares García M., Olea N., et al. Exposure to pesticides and cryptorchidism: geographical evidence of a possible association. Environ. Health Perspect. 104 (1996) 1090-1095
42. Garner M.J., Birkett N.J., Johnson K.C., Shatenstein B., Ghadirian P., Krewski D., and Canadian Cancer Registries Epidemiology Research Group. Dietary risk factors for testicular carcinoma. Int. J. Cancer 106 (2003) 934-941
43. Garner M., Turner M.C., Ghadirian P., Krewski D., and Wade M. Testicular cancer and hormonally active agents. J. Toxicol. Environ. Health B Crit. Rev. 11 (2008) 260-275
44. Gashaw I., Grummer R., Klein-Hitpass L., Dushaj O., Bergmann M., Brehm R., et al. Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4. Cell. Mol. Life Sci. 62 (2005) 2359-2368
45. Gashaw I., Dushaj O., Behr R., Biermann K., Brehm R., Rübben H., et al. Novel germ cell markers characterize testicular seminoma and fetal testis. Mol. Hum. Reprod. 13 (2007) 721-727
46. Gasparini G., Longo R., Toi M., and Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2 (2005) 562-577
47. Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Nigg E.A., et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J. Cell Biol. 166 (2004) 179-191
48. Hammerich K.A., Ayala G.E., and Wheele T. Application of immunohistochemistry to the genitourinary system (Prostate, Urinary Bladder, Testis, and Kidney). Arch. Pathol. Lab. Med. 132 (2008) 432-440
49. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10 (2004) 262-267
50. Hart A.H., Hartley L., Parker K., Ibrahim M., Looijenga L.H., Pauchnik M., et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 104 (2005) 2092-2098
51. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter L., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161 (2003) 281-294
52. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20 (2002) 1692-1703
53. Hoei-Hansen C.E., Almstrup K., Nielsen J.E., Brask Sonne S., Graem N., Skakkebaek N.E., et al. Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 47 (2005) 48-56
54. Horwich A., Shipley J., and Huddart R. Testicular germ-cell cancer. Lancet 367 (2006) 754-765
55. Jones R.H., and Vasey P.A. Part II: testicular cancer-management of advanced disease. Lancet Oncol. 4 (2003) 738-747
56. Jones T.D., Ulbright T.M., Eble J.N., Baldridge L.A., and Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am. J. Surg. Pathol. 28 (2004) 935-940
57. Katayama H., Ota T., Jisaki F., Ueda Y., Tanaka T., Odashima S., Suzuki F., et al. Mitotic kinase expression and colorectal cancer progression. J. Natl. Cancer Inst. 91 (1999) 1160-1162
58. Katayama H., Brinkley W.R., and Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22 (2003) 451-464
59. Keen N., and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4 (2004) 927-936
60. Kemmer K., Corless C.L., Fletcher J.A., McGreevey L., Haley A., Griffith D., et al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164 (2004) 305-313
61. Kim I., Saunders T.L., and Morrison S.J. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 130 (2007) 470-483
62. Korkola J.E., Heck S., Olshen A.B., Reuter V.E., Bosl G.J., Houldsworth J., et al. In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer 47 (2008) 43-55
63. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
64. Krausz C., and Looijenga L.H. Genetic aspects of testicular germ cell tumors. Cell Cycle 7 (2008) 3519-3524
65. Ledford H. Doubts raised over stem-cell marker. Nature (London) 449 (2007) 647
66. Lee D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 7 (2005) 89-91
67. Leibovitch I., Foster R.S., Ulbright T.M., and Donohue J.P. Adult primary pure teratoma of the testis: the Indiana experience. Cancer 75 (1995) 244-2250
68. Lengner C.J., Camargo F.D., Hochedlinger K., Welstead G.G., Zaidi S., and Gokhale S. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 1 (2007) 403-415
69. Leroy X., Augusto D., Leteurtre E., and Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J. Histochem. Cytochem. 50 (2002) 283-285
70. Li D., Zhu J., Firozi P.F., Abruzzese J.L., Evans D.B., Cleary K., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 9 (2003) 991-997
71. Liedtke S., Enczmann J., Waclawczyk S., Wernet P., and Kögler G. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 1 (2007) 364-366
72. Looijenga L.H. Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights. J. Pathol. 218 (2009) 146-162
73. Looijenga L.H., and Oosterhuis J.W. Pathogenesis of testicular germ cell tumours. Rev. Reprod. 4 (1999) 90-100
74. Looijenga L.H., Stoop H., de Leeuw H.P., de Gouveia Brazao C.A., Gillis A.J., van Roozendaal K.E., et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 63 (2003) 2244-2250
75. Looijenga L.H., de Leeuw H., van Oorschot M., van Gurp R.J., Stoop H., Gillis A.J., et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 63 (2003) 7674-7678
76. Lutke Holzik M.F., Rapley E.A., Hoekstra H.J., Sleijfer D.T., Nolte I.M., and Sijmons R.H. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol. 5 (2004) 363-371
77. Maatouk D.M., Loveland K.L., McManus M.T., Moore K., and Harfe B.D. Dicer1 is required for differentiation of the mouse male germline. Biol. Reprod. 79 (2008) 696-703
78. Madani A., Kemmer K., Sweeney C., Corless C., Ulbright T., Heinrich M., et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann. Oncol. 14 (2003) 873-880
79. Manova K., Nocka K., Besmer P., and Bachvarova R.F. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 110 (1990) 1057-1069
80. Martin O.V., Shialis T., Lester J.N., Scrimshaw M.D., Boobis A.R., and Voulvoulis N. Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Environ. Health Perspect 116 (2008) 149-157
81. Mayer F., Stoop H., Sen S., Bokemeyer C., Oosterhuis J.W., and Looijenga L.H.J. Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes. Oncogene 22 (2003) 3859-3866
82. McGlynn K.A., Quraishi S.M., Graubard B.I., Weber J.P., Rubertone M.V., and Erickson R.L. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J. Natl. Cancer Inst. 100 (2008) 663-671
83. Midgley R., and Kerr D. Bevacizumab-current status and future directions. Ann. Oncol. 16 (2005) 999-1004
84. Miyoshi Y., Iwao K., Egawa C., and Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 92 (2001) 370-373
85. Montgomery S.M., Granath F., Ehlin A., Sparén P., and Ekbom A. Germ-cell testicular cancer in offspring of Finnish immigrants to Sweden. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 280-282
86. Mosharafa A.A., Foster R.S., Leibovich B.C., Ulbright T.M., Bihrle R., and Einhorn L.H. Histology in mixed germ cell tumors: is there a favorite pairing?. J. Urol. 171 (2004) 471-1473
87. Mostofi F.K., Sesterhenn I.A., and Davis Jr. C.J. Developments in histopathology of testicular germ cell tumors. Semin. Urol. 6 (1988) 171-188
88. Müller J., Skakkebaek N.E., Nielsen O.H., and Graem N. Cryptorchidism and testis cancer. Atypical infantile germ cells followed by carcinoma in situ and invasive carcinoma in adulthood. Cancer 54 (1984) 629-634
89. Nieder C., Wiedenmann N., Andratschke N., and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat. Rev. 32 (2006) 348-364
90. Nielsen H., Nielsen M., and Skakkebaek N.E. The fine structure of possible carcinoma-in-situ in the seminiferous tubules in the testis of four infertile men. Acta Pathol. Microbiol. Scand. A. 82 (1974) 235-248
91. Oosterhuis J.W., and Looijenga L.H. Testicular germ-cell tumors in a broader perspective. Nat. Rev. Cancer 5 (2005) 210-222
92. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 62 (2002) 5168-5177
93. Palumbo C., van Roozendaal K., Gillis A.J., van Gurp R.H., de Munnik H., Oosterhuis J.W., et al. Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J. Pathol. 196 (2002) 467-477
94. Peckham M. Testicular cancer. Acta Oncol. 27 (1988) 439-453
95. Perrett R.M., Turnpenny L., Eckert J.J., O'Shea M., Sonne S.B., Cameron I.T., et al. The early human germ cell lineage does not express SOX2 during in vivo development or upon in vitro culture. Biol. Reprod. 78 (2008) 852-858
96. Perrotti M., Ankem M., Bancilla A., deCarvalho V., Amenta P., and Weiss R. Prospective metastatic risk assignment in clinical stage I nonseminomatous germ cell testis cancer: a single institution pilot study. Urol. Oncol. 22 (2004) 174-177
97. Porcaro A.B., Antoniolli S.Z., Maffei N., Beltrami P., Bassetto M.A., and Curti P. Management of testicular seminoma advanced disease: report on 14 cases and review of the literature. Arch. Ital. Urol. Androl. 74 (2002) 81-85
98. Pottern A. Testicular and penile cancer. Ernstoff Heaney Peschel (1998), Blackwell Science, Oxford, UK
99. Rajpert-De Meyts E., Bartkova J., Samson M., Hoei-Hansen C.E., Frydelund-Larsen L., Bartek J., and Skakkebaek N.E. The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 111 (2003) 267-278
100. Ranieri G., Patruno R., Ruggirei E., Montemurro S., Valerio P., and Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 1 (2006) 1845-1847
101. Rapley E.A., Hockley S., Warren W., Johnson L., Huddart R., Crockford G., et al. Somatic mutations of KIT in familial testicular germ cell tumours. Br. J. Cancer 90 (2004) 2397-2401
102. Ro J.Y., Amin M.B., Sahin A.A., and Ayala A.G. Tumors and tumorous conditions of the male genital tract. In: Fletcher C.D.M. (Ed). Diagnostic Histopathology of Tumors. 2nd ed. (2000), Churchill Livingstone, London, England 733-838
103. Rodriguez P.N., Hafez G.R., and Messing E.M. Nonseminomatous germ cell tumor of the testicle: does extensive staging of the primary tumor predict the likelihood of metastatic disease?. J. Urol. 136 (1986) 604-608
104. Rossi P., Sette C., Dolci S., and Geremia R. Role of c-kit in mammalian spermatogenesis. J. Endocrinol. Invest. 64 (2000) 1153-1159
105. Sakakura C., Hagiwara A., Yasuoka R., Fujita Y., Nakanishi M., Masuda K., et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer 84 (2001) 824-831
106. Sen S., Zhou H., Zhang R.D., Yoon D.S., Vakar-Lopez F., Ito S., et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J. Natl. Cancer Inst. 94 (2002) 1320-1329
107. Shamblott M.J., Axelman J., Wang S., Bugg E.M., Littlefield J.W., Donovan P.J., et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. USA 95 (1998) 13726-13731
108. Shelley M.D., Burgon K., and Mason M.D. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat. Rev. 28 (2002) 237-253
109. Skakkebaek N.E. Possible carcinoma-in-situ of the testis. Lancet 2 (1972) 516-517
110. Skakkebaek N.E., Berthelsen J.G., Giwercman A., and Müller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl. 10 (1987) 19-28
111. Strohsnitter W.C., Noller K.L., Hoover R.N., Robboy S.J., Palmer J.R., Titus-Ernstoff L., et al. Cancer risk in men exposed in utero to diethylstilbestrol. J. Natl. Cancer Inst. 93 (2001) 545-551
112. Takahashi T., Futamura M., Yoshimi N., Sano J., Katada M., Takagi Y., et al. Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jap. J. Cancer Res. 91 (2000) 1007-1014
113. Talerman A. Spermatocytic seminoma: clinicopathological study of 22 cases. Cancer 45 (1980) 2169-2176
114. Tanaka T., Kimura M., Matsunaga K., Fukada D., Mori H., and Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 59 (1999) 2041-2044
115. Tatsuka M., Katayama H., Ota T., Tanaka T., Odashima S., Suzuki F., et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res. 58 (1998) 4811-4816
116. Terada Y., Tatsuka M., Suzuki F., Yasuda Y., Fujita S., and Otsu M.A. AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J. 17 (1998) 667-676
117. Theakera J.M., and Meadb G.M. Diagnostic pitfalls in the histopathological diagnosis of testicular germ cell tumours. Curr. Diagnostic Pathol. 10 (2004) 220-228
118. Ulbright T.M. Germ cell neoplasm of the testis. Am. J. Surg. Pathol. 17 (1993) 1075-1091
119. Ulbright T.M. Protocol for the examination of specimens from patients with malignant germ cell and sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies: a basis for checklists. Arch. Pathol. Lab. Med. 123 (1999) 14-19
120. Ulbright T.M. Testicular and paratesticular tumors. In: Mills S.E. (Ed). Sternberg's Diagnostic Surgical Pathology. 14th ed. (2004), Lippincott Williams & Wilkins, Philadelphia, PA 2173-2176
121. Ulbright T.M. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Modern Pathol. 18 (2005) S61-S79
122. Vader G., Medema R.H., and Lens S.M. The chromosomal passenger complex: guiding Aurora-B through mitosis. J. Cell Biol. 173 (2006) 833-837
123. Van de Geijn G.J.M., Hersmus R., and Looijejnga L.H. Recent developments in testicular germ cell tumor research. Birth Defects Res. (Part C) 87 (2009) 96-113
124. Verdorfer I., Rogatsch H., Tzankov A., Steiner H., and Mikuz G. Molecular cytogenetic analysis of human spermatocytic seminomas. J. Pathol. 204 (2004) 277-281
125. von Eyben F.E. Laboratory markers and germ cell tumors. Crit. Rev. Clin. Lab. Sci. 40 (2003) 377-427
126. Voorhoeve P.M., le Sage C., Schrier M., Gillis A.J., Stoop H., Nagel R., et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 12 (2006) 1169-1181
127. Weissbach L., Bussar-Maatz R., Lohrs U., Schubert G.E., Mann K., Hartmann M., et al. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study: Seminoma Study Group. Eur. Urol. 36 (1999) 601-608
128. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66 (2006) 1883-1890
129. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 1 (2007) 3682-3688
130. Yamaguchi S., Kimura H., Tada M., Nakatsuji N., and Tada T. Nanog expression in mouse germ cell development. Gene Expr. Patterns 5 (2005) 639-646
131. Yates A., and Chambers I. The homeodomain protein Nanog and pluripotency in mouse embryonic stem cells. Biochem. Soc. Trans. 33 Part 6 (2005) 1518-1521
132. Young R.H. Testicular tumors-some new and a few perennial problems. Arch. Pathol. Lab. Med. 132 (2008) 548-564
133. Zakarija A., and Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 6 (2005) 578-583
134. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneploidy and transformation. Nat. Genet. 20 (1998) 189-193